Thrombosis in COVID-19

Link to article at PubMed

Am J Hematol. 2020 Aug 28. doi: 10.1002/ajh.25982. Online ahead of print.


Thrombotic complications are frequent in COVID-19 and contribute significantly to mortality and morbidity. We review several mechanisms of hypercoagulability in sepsis that may be upregulated in COVID-19. These include immune-mediated thrombotic mechanisms, complement activation, macrophage activation syndrome, antiphospholipid antibody syndrome, hyperferritinemia, and renin-angiotensin system dysregulation. We highlight biomarkers within each pathway with potential prognostic value in COVID-19. Lastly, recent observational studies have evaluated a role for the expanded use of therapeutic anticoagulation in COVID-19. We review strengths and weaknesses of these studies, and we also discuss the hypothetical benefit and anticipated challenges of fibrinolytic therapy in COVID-19. This article is protected by copyright. All rights reserved.

PMID:32857878 | DOI:10.1002/ajh.25982

Leave a Reply

Your email address will not be published. Required fields are marked *